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Nicotinic acid phosphoribosyltransferase (EC 2.4.2.11) (NaPRTase) is the rate-limiting enzyme in the
three-step Preiss–Handler pathway for the biosynthesis of NAD. The enzyme catalyzes the conver-
sion of nicotinic acid (Na) and 5-phosphoribosyl-1-pyrophosphate (PRPP) to nicotinic acid mononu-
cleotide (NaMN) and pyrophosphate (PPi). Several studies have underlined the importance of
NaPRTase for NAD homeostasis in mammals, but no crystallographic data are available for this
enzyme from higher eukaryotes. Here, we report the crystal structure of human NaPRTase that
was solved by molecular replacement at a resolution of 2.9 Å in its ligand-free form. Our structural
data allow the assignment of human NaPRTase to the type II phosphoribosyltransferase subfamily
and reveal that the enzyme consists of two domains and functions as a dimer with the active site
located at the interface of the monomers. The substrate-binding mode was analyzed by molecular
docking simulation and provides hints into the catalytic mechanism. Moreover, structural compar-
ison of human NaPRTase with the other two human type II phosphoribosyltransferases involved in
NAD biosynthesis, quinolinate phosphoribosyltransferase and nicotinamide phosphoribosyltrans-
ferase, reveals that while the three enzymes share a conserved overall structure, a few distinctive
structural traits can be identiﬁed. In particular, we show that NaPRTase lacks a tunnel that, in nicoti-
namide phosphoribosiltransferase, represents the binding site of its potent and selective inhibitor
FK866, currently used in clinical trials as an antitumoral agent.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Nicotinamide adenine dinucleotide (NAD) and its phosphory-
lated form (NADP) are essential ubiquitous coenzymes playing fun-
damental roles in living cells. Beyond renown redox roles in energy
metabolism, NAD(P) is also intimately involved in signaling path-
ways through a number of consuming reactions that underscore
a wealth of physiopathological conditions [1–4]. Indeed, the
NAD(P) derivatives nicotinic acid adenine dinucleotide phosphate(NaADP) and cyclic ADP-ribose (cADPR) are among the most potent
intracellular calcium-mobilizing agents [4,5]. Moreover, NAD is the
substrate for poly(ADP-ribosyl)ation reactions that in higher
eukaryotes regulate chromatin function and gene expression, as
well as for mono(ADP-ribosyl)ation modiﬁcations of target pro-
teins in both mammalian and prokaryotic cells [4]. In all organ-
isms, NAD can also be consumed by important regulatory
enzymes, named sirtuins, that catalyze NAD-dependent deacetyla-
tion reactions of target proteins [6]. Clearly, physiological NAD
depletion caused by overall NAD-consuming reactions necessitates
permanent regeneration of this cofactor. Therefore NAD biosynthe-
sis appears of therapeutically value for the treatment of patholog-
ical conditions arising from severe altering of NAD(P) homeostasis
like in the case of neurological, neoplastic, and infectious disorders,
as well as in the process of ageing [1,3,7–10]. Based on current
knowledge, four different substrates can be used as a source of
the pyridine ring in the NAD biosynthesis: quinolinic acid (QA) in
the de novo pathway; nicotinic acid (Na), nicotinamide (Nam)
and nicotinamide riboside (NamR) in the salvage pathways.
While this latter compound is phosphorylated by action of an
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Na and Nam, can be individually transferred to a phosphoribosyl
pyrophosphate moiety (PRPP) by respective phosphoribosyl-
transferase activities [12]. The resulting mononucleotide products,
nicotinic acid mononucleotide (NaMN) and nicotinamide mononu-
cleotide (NMN), are then converted to dinucleotide forms, i.e. nico-
tinic acid dinucleotide (NaAD) and NAD, by action of a single
enzymatic activity represented by nicotinamide mononucleotide
adenylyltransferase (NMNAT) [13,14]. NaAD is ﬁnally amidated
to NAD by a NAD synthetase activity (Fig. 1) [7,12,15].
Although the Nam salvaging biosynthetic route appears physio-
logically the main contributor to keep adequate NAD homeostasis
[16–18], the supplementation of Nam does not seem so effective in
elevating cellular NAD beyond the basal concentration. Indeed,
some mammalian tissues like heart, kidney [19], and red blood
cells [20] use preferentially Na for NAD synthesis even in the pres-
ence of higher Nam levels physiologically available [21]. Thus, both
precursors appear relevant for NAD biosynthesis but with distinct
and possibly complementary roles in different tissues [22]. This
view is also supported by the observation that human embryonic
kidney (HEK293) cell line, when supplemented with Na, but not
with Nam, markedly elevated intracellular NAD levels, and showed
beneﬁcial effects versus the cytotoxic stress symptoms caused by
H2O2 [22]. This effect of exogenously administered Na likely
accounts for at least some effects of this vitamin precursor andTrp
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Fig. 1. Metabolic pathway for NAD(P) biosynthesis in humans. NAD biosynthesis startin
through four distinct ways. The de novo pathway (blue dotted line) allows NAD biosyn
Preiss–Handler pathway enzymes (green dotted line). Through a salvage pathway Nam a
Finally, some of the cellular NAD can be converted into NADP by NAD kinase (EC 2.7.1
nicotinic acid phosphoribosyltransferase (EC 2.4.2.11); NMPRTase, nicotinamide phosp
2.7.1.22); NMNAT nicotinamide mononucleotide adenylyltransferase (EC 2.7.7.1); NADSsuggests novel applications for the treatment of conditions associ-
ated with cellular NAD depletion, such as in photodamaged skin
[23]. Of note in this context is also the ﬁnding that Na is one of
the oldest drugs known for its unique anti-lipolytic effects [24],
that has been attributed in more recent years to its speciﬁc binding
to selected receptors present on the plasma membrane of adipo-
cytes [25,26]. In mammals, Na can derive either directly from the
diet, or indirectly from the enzymatic deamidation of dietary
Nam operated by the gut ﬂora. As shown in Fig. 1, Nicotinate
Phosphoribosyltransferase (EC 2.4.2.11) is the ﬁrst enzyme that
catalyzes the synthesis of NaMN and PPi from Na and PRPP. The
enzyme, originally named NaMN pyrophosphorylase, was ﬁrst
described by Handler in human erythrocytes, where it plays a
key role in elevating NAD levels [20]. In both mice and humans,
NaPRTase appears differentially expressed in tissues, being more
abundant where Na is the preferential source for NAD biosynthesis
[22,27]. Like the bacterial counterpart enzymes, human NaPRTase
is strictly speciﬁc for Na as a substrate and ADP, NaAD and NAD
do not affect its activity [27,28]. The central compounds of cellular
metabolism, ATP and Pi, were found to affect human NaPRTase
(hNaPRTase) activity. In particular ATP utilization seems to pro-
mote allosteric interactions between subunits [27]. Such
ATP-driven conformational change can also be inferred by the
observation that, in microbial NaPRTs, ATP binding protects from
proteolysis [29] and heat inactivation [30].NADP
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g from four different sources of the pyridine ring, namely QA, Na, Nam and NamR,
thesis starting from QA derived from Trp and Na is processed to NAD through the
nd NamR can be transformed in NMN by NMPRTase and NamRKinase respectively.
.23). QAPRTase, quinolinic acid phosphoribosyltransferase (EC 2.4.2.19); NaPRTase,
horibosyltransferase (EC 2.4.2.12); NamRKinase, nicotinamide riboside kinase (EC
, NAD synthetase (EC 6.3.5.1).
Table 1
Data collection and reﬁnement statistics.
hNaPRTase crystal
Data collection
Space group P212121
Cell dimensions
a, b, c (Å) 88.0, 101.1, 125.1
a, b, c () 90, 90, 90
Resolution (Å) 2.9
Rpim/Rmerge 6.1 (20.5)/11.4 (37)
Mean(I)/sd(I) 10.0 (3.7)
Completeness (%) 99.7 (99.3)
Redundancy 4.4 (4.2)
Reﬁnement
Resolution (Å) 2.9
No. reﬂections 25,261 (2464)
Rwork/Rfree 0.19/0.24
No. atoms
Protein 7576
Water 98
Mean B-factors
Protein (Å2) 42.67
Water (Å2) 33.60
R.m.s deviations
Bond lengths (Å) 0.014
Bond angles () 1.83
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thesis in mammalian cells, several evidences indicate its comple-
mentary role in boosting and regulating NAD biosynthesis under
certain conditions and in speciﬁc local districts [17]. This role
appears equally relevant as that proposed for other enzymes of
the same pathway, particularly in the context of possible treat-
ments of NAD-related diseases.
Here we report on the crystal structure of the human enzyme in
its free form that has been determined at a 2.9 Å resolution. Such
structural analysis was instrumental to (i) establish the protein
folding conservation among enzymes catalyzing similar phospho-
ribosyltransferase reactions but using different pyridine substrates,
and thus complete the structural information on the NAD salvage
pathway enzymes in mammals, (ii) shed further light on the cat-
alytic mechanism of the hNaPRTase and (iii) provide a structural
basis for the lack of inhibition on NaPRTase by antitumor drugs tar-
geting NAD biosynthesis metabolism [31]. Moreover, being the
ﬁrst structural report of this enzyme from a mammalian source,
it may also assist future structure-based design of effectors of
potential medical interest.
2. Experimental procedures
2.1. Enzyme expression and puriﬁcation
The procedure adopted for the human gene cloning and bacte-
rial overexpression of recombinant human NaPRTase has been pre-
viously reported [28] and here adjusted as follows. Induced cells
collected by centrifugation were resuspended in 1/50 original vol-
ume with 100 mM KH2PO4, pH 8, 300 mM KCl, 10 mM imidazole,
1 mM b-mercaptoethanol and 250 units of benzonase nuclease.
Bacterial cells membranes were fragmented by applying a high
pressure through the use of the French Press twice at 1.5 K Bar.
Protease inhibitor cocktail was added (100 lL per 40 mL extraction
Buffer) to the crude extract that was clariﬁed by 1 h centrifugation
at 18,000 rpm. The supernatant was puriﬁed by a His-tag afﬁnity
chromatography and a subsequent size-exclusion chromatogra-
phy. In particular, in the ﬁrst puriﬁcation step, the solution con-
taining the soluble fraction of human enzyme was batch-mixed
for 30 min with a Qiagen Ni-NTA resin (0.1 mL per mL extract), pre-
viously equilibrated with the buffer, and then packed into a chro-
matographic column. The ﬂow-through and the 30 mM imidazole
buffer wash were discarded. The recombinant protein was eluted
by two subsequent steps at 250 and 500 mM imidazole. Protein
concentration was determined by the Bradford protein assay.
Active, SDS–PAGE homogeneous fractions, were pooled, cen-
trifuged and loaded on a Sephacryl S200 16/60 column in a FPLC
system. Elution Buffer contained 50 mM Hepes/KOH buffer, pH
7.5, and 300 mM KCl and the ﬂow rate was 0.2 mL/min. Eluted
fractions were analyzed by SDS–PAGE. All steps were performed
at 4 C and with 100 lL/40 mL Protease Inhibitor cocktail to pre-
serve the protein stability. The hNaPRTase activity was tested using
the assay previously reported [28] and resulted to be
0.27 lmol/min/mg. Using the same assay condition we tested the
activity of human NaPRTase in presence of 100 lM FK866 without
observing any inhibition of enzyme activity. This procedure
allowed us to obtain 20 mg of pure and active human enzyme used
for all crystallization trials.
2.2. Crystallization and structure determination
Crystals of hNaPRTase were obtained by means of the vapor dif-
fusion technique in sitting drops. 4 lL of a protein solution at a
concentration of 15 mg/mL, preincubated with 1 mM Acetyl-CoA
and 5 mM DTT, were mixed with an equal volume of a reservoirsolution containing 0.1 M Sodium cacodylate pH 6.5 and 1.7 M
Sodium acetate and equilibrated against 1.2 mL of the reservoir
solution, at 4 C. Crystals grew to maximum dimension in about
5 days. For X-ray data collection, crystals were quickly equilibrated
in a solution containing the crystallization buffer and 20% glycerol
as the cryo-protectant and ﬂash frozen at 100 K under a stream of
liquid nitrogen. Data up to 2.9 Å resolution were collected at the
beamline ID23 EH1 of the European Synchrotron Radiation
Facility (ESRF, Grenoble, France). Analysis of the diffraction data
set collected allowed us to assign the crystal to the orthorhombic
P212121 space group with cell dimensions a = 88.0 Å b = 101.1 Å
and c = 125.1 Å containing two molecules per asymmetric unit
with a corresponding solvent content of 49%. Data were processed
using the program package XDS [32] and the CCP4 suite of program
[33] were used for scaling. The structure determination of
hNaPRTase was carried out by means of the molecular replacement
technique using the coordinates of a monomer of Enterococcus fae-
calis NaPRTase as the search model (Protein Data Bank ID code
2F7F). Firstly, an improvement of the quality of the search model
was carried out by using information contained in the sequence
alignment between the hNaPRTase and the E. faecalis NaPRTase
through the program SCULPTOR [34]. The new procedure
Phenix.mr_rosetta [35], that combines crystallographic and
structure-modeling algorithms from Phenix and Rosetta, respec-
tively, was used to automatically determine the hNaPRTase struc-
ture. Phenix.mr_rosetta returned a unique molecular replacement
solution with an LLG of 44.56 and TFZ = 7.4. The initial model
was subjected to iterative cycles of crystallographic reﬁnement
with the program REFMAC5 [36], alternated with manual graphic
sessions for model building using the program Coot [37]. 5% of ran-
domly chosen reﬂections were excluded from reﬁnement of the
structure and used for the Free R factor calculation [38]. The pro-
gram ARP/warp [39] was used for adding solvent molecules.
Reﬁnement was continued until convergence to R factor and Free
R factor of 0.19 and 0.24 respectively with ideal geometry. Data
collection and reﬁnement statistics are given in Table 1.
2.3. Molecular modeling
A molecular dynamics simulation was performed using the
GROMACS simulation package v.4.5.3 [40] with the standard
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was energy-minimized in vacuo, using 1000 steps of steepest des-
cent in order to remove distorted geometries and with the protein
embedded in a solvent box. The next step was a 2 ns simulation
with position restraints to the protein, followed by a 500 ps unre-
strained simulation. The last 500 ps of the simulation were used to
compute an average structure for hNaPRTase, which, after mini-
mization with 1000 steps of steepest descent, represents the ﬁnal
model. After aminoacids stereochemistry has been assessed with
the program PROCHECK [41], the model was used for docking sim-
ulations. The ligands tested for docking were FK866, Na, NaMN, Na
plus PRPP and ATP. Ligand structures were built from a SMILES
string and were minimized using Omega2 [42]. The docking simu-
lations were performed using FRED, and using the default settings
[43]. Each ligand-NaPRTase complex was subsequent subjected to
a molecular structure optimization using SZYBKI [44] in order to
reﬁne the molecular structure using the Merck Molecular Force
Field with solvent effect.
2.4. Deposition
The atomic coordinates and structure factors of human
NaPRTase have been deposited with the Protein Data Bank
(www.rcsb.org) with accession code: 4YUB.
2.5. Illustrations
Figures were generated by using the program pymol [45].
3. Results and discussion
3.1. Overall quality of the model
The three-dimensional structure of hNaPRTase has been solved
by molecular replacement and reﬁned at a resolution of 2.9 Å. The
crystal asymmetric unit contains a dimer of hNaPRTase and a total
of 98 solvent molecules. The two protein molecules have been des-
ignated as monomers A and B (Fig. 2). Monomer A contains 501
residues out of 538 and no electron density is present for the fol-
lowing regions: ﬁrst 15 residues at the N-terminus, residues
379–389, residues 409–415, and last ﬁve residues at the
C-terminus. Monomer B contains 501 residues out of 538 and no
electron density is present for the following regions: ﬁrst 15 resi-
dues at the N-terminus, residues 379–389, residues 408–414,
and last four residues at the C-terminus. The stereochemistry of
the model has been assessed with the program PROCHECK [41]:
99% of protein residues fall in the favoured regions of the
Ramachandran plot with no outliers.
3.2. Overall structure of human NaPRTase monomer
Human NaPRTase monomer folds into 17 a-helices, 24
b-strands and the connecting loops organized in two domains: a
ﬁrst domain characterized by an irregular a/b barrel and a second
open-faced sandwich domain (Fig. 3). In particular, as shown in the
protein topology diagram in Fig. 3, the open-face sandwich domain
is composed of residues provided by both the N- and C-terminal
regions of the protein (residues 16–127 and 390–534). It consists
of 4 a-helices disposed like a shield and delimiting the open space
where 15 b-strands form 2 antiparallel b-sheets, showing a specu-
lar two-by-two arrangement. Indeed, the seven-stranded fully
antiparallel b-sheet (b1, b3, b5, b15, b16, b22 and b23) and the
four-stranded partially antiparallel b-sheet (b17, b18, b21 and
b24) face each other. The other two smaller b-sheets (b2, b4 and
b19, b20) delimit the domain. The longest helix a5, with 8 turns(residues 128–159) connects the two domains. The irregular a/b
barrel domain (residues 160–378) contains a six-stranded a/b core
(b6, b7, b11, b12, b13, and a6, a11, a12, a13, a14) that identiﬁes
hNaPRTase as a member of the type II
Phosphoribosyltransferases (PRTases) subfamily. The two mono-
mers present in the asymmetric unit have the same conformation
showing a r.m.s. deviation of 0.5 Å after superposition based on all
Ca atoms. The hNaPRTase structural organization turns out to be
highly similar to that of E. faecalis NaPRTase, used as a model for
the molecular replacement. Indeed, the two structures can be opti-
mally superimposed with a r.m.s.d. of 2.4 Å based on 482 equiva-
lent Ca atoms. As could be expected, the overall fold is highly
conserved with two domains connected by a long a-helix.
Moreover, in spite of the low sequence identity (34%) the active
site residues are conserved in the two enzymes revealing an iden-
tical mode of binding for substrates. In particular, Y17, H205, R262,
S206 K333 R163 and T162 that in E. faecalis NaPRTase deﬁnes the
enzyme active site are strictly conserved in hNaPRTase with equiv-
alent positions occupied by Y21, H213, R318, S214 K396 R171 and
L170. The high degree of structural conservation observed between
the human and the bacterium NaPRTases could be due to an evo-
lutionary adaptation. Indeed, E. faecalis is a commensal bacterium
inhabiting the gastrointestinal tracts of humans where, in the
small intestine, Na is a preferred source for NAD synthesis.
3.3. The dimer of human NaPRTase
hNaPRTase has a predicted molecular weight of 58 KDa and it
has been reported to show a native molecular mass of about
87,000 Da by gel ﬁltration [46,28]. The crystal structure of
hNaPRTase reveals the presence of an intimately associated dimer
in the asymmetric unit with 3000 Å2 of the surface area buried at
the dimer interface. The two monomers are arranged head to tail
with the N-terminal domain in one monomer contacting the a/b
barrel in the other monomer (Fig. 2). Therefore our structural data
conﬁrm that the minimal functional unit in the hNaPRTase enzyme
consists of a dimer as already proposed for Thermoplasma aci-
dophilum NaPRTase [47]. Moreover, the major interactions estab-
lished at the dimeric interface in TaNaPRTase were observed to
be of ionic rather than hydrophobic nature [47]. Our structural
analysis conﬁrmed that the main interactions between monomers
are of ionic nature also in hNaPRTase.
3.4. The active site
Since we have been unable to obtain crystals of hNaPRTase in
complex with any ligand, the binding mode of substrate/product
to the enzyme active site was investigated through molecular
docking simulations. The functional dimeric model of hNaPRTase
was ﬁrst re-built using the X-ray crystal structure and subse-
quently reﬁned by molecular dynamics simulations. Na, NaMN,
Na plus PRPP, and ATP were docked in the generated model. As
already reported in the previously characterized NaPRTases [47],
the active site consists of a pocket located at the dimer interface.
In particular, in hNaPRTase it is delimited by the loops connecting
a-helix 6 with b-strand 6 and a-helix 8 with b-strand 8 of a/b bar-
rel domain of monomer A and completed by residues of b-strand
11 and a-helix 1 from monomer B (Fig. 4). According to our mod-
eling procedure the pyridine ring of Na establishes contacts with
the protein environment that involve a p–p stacking interaction
with Y21B and Van der Walls contacts with L170A, G209A and
L211A. In addition, the carboxyl group of Na is engaged in a strong
ionic interaction with R318A (Fig. 5a). It has previously been
reported that the G201 to Ala substitution causes a 90% reduction
of enzyme activity even in the presence of ATP and that the Y21 to
Ala substitution results in the complete loss of activity in absence
N-ter
N-ter
C-ter
C-ter
A
B
A B
C-ter
C-ter
N-ter
N-ter
Fig. 2. Overall oligomeric structure of human NaPRTase. The enzyme has a dimeric structure and monomers A and B are colored in orange and green, respectively. Two
different orientations of the dimer, showing the head-to-tail arrangement of the monomers, are represented. N-ter, N-terminus; C-ter, C-terminus.
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are therefore in agreement with the functional analysis carried out
by site directed mutagenesis and provide a solid structural expla-
nation for the role played by these residues in catalysis. We then
investigated the mode of binding for Na and PRPP when simultane-
ously bound to the enzyme active site (Fig. 5b). PRPP appears to be
stabilized by two ionic interactions with R171A and K396B that are
engaged in a salt bridge with the phosphate and pyrophosphate
moieties, respectively. PRPP is further stabilized by two hydrogen
bonds established between its ribose oxygen and R318A and
between the pyrophosphate moiety and S214A. Our observations
conﬁrm the functional analysis carried out by site-directed muta-
genesis previously reported in which the replacement of R318 with
Ala completely abolish the enzyme activity in absence of ATP while
a reduction of 50% is observed in the presence of ATP [28]. The ATP
binding mode was also investigated and turned out to be quite
similar to that observed for PRPP (Fig. 5d). In particular the ATP
c phosphate group is salt bridged to K396B, one of the key residue
for PRPP binding, while the b phosphate group is involved in
hydrogen bonds with H213A (backbone amide) and S214A. The
adenine moiety of ATP is involved in a p-polar interaction with
R318A. Also in this case, our observations remark an important role
in catalysis for H213 that when mutated to Ala was reported to
cause a 50% reduction of the enzyme activity [28]. Finally, the
binding mode of the product NaMN was investigated (Fig. 5c). As
expected, the orientation of both the Na and phosphate moieties
in the mononucleotide, is identical to what observed for the corre-
sponding chemical entities in the model of the Na-PRPP enzyme
complex. In conclusion, our structural models for substrate binding
provide a solid explanation for the role played in catalysis by resi-
dues that were previously reported to be essential for enzyme
activity by a functional analysis based on site directed mutagenesis
[28]. The perfect coherence between biochemical data reported in
previous study and our structural observations, also proves that
our molecular docking simulation are robust. Therefore, besides
R318, Y21, H213 that were already subjected to site directed muta-
genesis and that we conﬁrm to be essential residues for catalysis,
we propose that R171, K396 and S214 also play an essential role
in substrate recognition. Moreover, we identify R318 as the majorplayer in catalysis. Indeed, this residue is involved in the binding of
all substrates by recognizing different chemical entities: the car-
boxylic moiety of Na, the ribose ring of PRPP and the adenine base
of ATP. In addition, our in silico model of the complex hNaPRT-Na
and hNaPRT-NaMN allows a detailed structural comparison of
the mode of binding of Na, Nam and QA in the three phosphoribo-
syltransferases. At the level of the active sites we observe a high
degree of structural conservation mainly between hNaPRTase and
hNMPRTase, while a less signiﬁcant conservation is observed with
hQAPRTase. However, the mode of binding of all the three different
pyridines is conserved, while different is the protein milieu sur-
rounding the substrate. In particular, hQAPRTase provides a more
positively charged environment that is required for the recognition
of QA that carries two negatively charged carboxylic groups.
Although our structural analysis does not disclose any obvious
common features for the catalytic mechanism adopted by
hQAPRTase, hNMPRTase and hNaPRTase, a conserved mode of
binding of the pyridine ring containing substrate clearly emerges.
More information can be extracted if the structural analysis is con-
ﬁned to hNaPRTase and hNMPRTase. In these two enzymes, the
mode of binding of Na and Nam appears highly similar. Indeed,
the pyridine ring is sandwiched by an aromatic/hydrophobic clamp
in both enzymes: Y18/F193 in hNMPRTase and Y21/L170 in
hNaPRTase. R311, R196 and K400 that in hNMPRTase play a key
role in the binding of PRPP, are strictly conserved in hNaPRTase
(R318, R171 and K396). On the other hand, a speciﬁc residue
appears to participate in guaranteeing the strikingly substrate
speciﬁcity displayed by hNMPRTase and hNAPRTase for nicoti-
namide versus nicotinic acid. While in hNMPRTase D219 interacts
with the amide moiety of Nam, in hNaPRTase the structurally
equivalent position is occupied by S214 contributing to direct the
enzyme speciﬁcity toward nicotinate. Other structural determi-
nants that do not clearly emerge in our docking models are how-
ever required to fully explain the strict speciﬁcity toward
nicotinic acid displayed by hNaPRTase. Overall, a conserved mode
of binding of QA, Na and Nam in the respective phosphoribosyl-
transferase is observed. However, the structural architecture of
the active site is sensibly different in hQAPRTase and peculiar traits
also feature hNMPRTase and hNaPRTase. Therefore, we propose
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Nα1
α17
C
α5
β5β3β22β23 β16β15
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β20
β19
β18β17β21
β1
β2
β4
β11
β12
β13
β14
β6
β8
α6
α11
α12 α13
α14
α2α3α4
α7
α8
α9
α10
β9β10
β7
open-faced sandwich domain
Fig. 3. Overall monomer structure of human NaPRTase. Ribbon representations of the overall structure of hNaPRTase monomer. Each monomer consists of two domains: the
‘‘open-faced sandwich domain’’ is shown in yellow, while the ‘‘irregular a/b barrel domain’’ is colored orange. The two domains are connected by a long a-helix, colored in
gray. The topology model of the monomer highlight that the ‘‘open-face sandwich domain’’ is composed of residues by both the N- and C-terminal regions and the ‘‘irregular
barrel domain’’ contains a six-stranded a/b core.
424 A.S. Marletta et al. / FEBS Open Bio 5 (2015) 419–428that the wealth of structural information that is now available for
all the three enzymes can be successfully exploited for the design
of highly selective inhibitors.
3.5. Comparison with hNMPRTase and hQAPRTase
Despite sharing very limited sequence similarity, hNaPRTase
shows a molecular fold that closely resembles those ﬁrstly
described for hNMPRTase [31,48] and hQAPRTase [49] (Fig. 6).
This fact is in accordance with their common function, consisting
in the transfer of the phosphoribosyl group from PRPP onto their
respective substrates. A DALI search shows a signiﬁcant similarity
with hNMPRTase with a Z-value of 22.2 and a r.m.s. deviations of
3.6 Å based on superposition of 463 equivalent Ca atoms.hQAPRTase is the smallest in size among the three PPRTases, in
agreement with the hypothesis that it is the most ancient [50].
At the contrary, hNaPRTase contains 46 and 241 more amino acid
residues than hNMPRTase and hQAPRTase, respectively. The struc-
tural superposition of the three enzymes highlights how some of
the additional residues in hNaPRTase form two structural regions
that, from a Blastp search, appear to be univocally present in mam-
mal NaPRTases (Fig. 6). The ﬁrst unique region spans amino acids
223–264 and contains two b-strands (b9–b10) and one a-helix
(a9) that extend the borders of the a/b barrel domain and con-
tribute to contact the other monomer (Fig. 3). Indeed, the side
chain of D227 is hydrogen bonded to the side chain of R31 of the
opposite monomer. The second unique region (447–472) of
hNaPRTase encompasses three b-strands (b19, b20 and b21) that
β−8
β−6
α−6
α−8
α−1
β−11
R 318
H 213
S 214
K 396Y 21
R 171
L 170
Fig. 4. Active site representation of human NaPRTase. Ribbon representation of the
active site formed at the dimeric interface, between the a/b barrel domain of
monomer A, colored in orange, and the monomer B, shown in green. Side chains of
key residues involved in catalysis are shown.
A.S. Marletta et al. / FEBS Open Bio 5 (2015) 419–428 425stand at the bottom of the open-faced sandwich (Fig. 3). These two
peculiar regions in hNaPRT are located on the enzyme surface and
do not have any structural impact on the enzyme active site.Na
R 318
H 213
R 171
L 170
G  209
S 214
I 378
A B
NaMN
R 318
H 213
R 171
L 170
G  209
S 214
I 378
C D
Fig. 5. Molecular docking of the hNaPRTase active site dimeric interface in complex with
(B) NaMN; (C) Na and PRPP; (D) ATP) are represented as thin sticks and their identity is in
yellow dotted lines.Therefore, there is no evidence of their involvement in catalysis
or substrate binding. On the other hand, since the activity of extra-
cellular hNMPRTase as a potent cytokine is well documented [51],
we speculate that the structural variation of the protein surface
may sustain still unknown functions of an extracellular form of
hNaPRTase. The analysis of conserved versus peculiar traits in
the active site of the three human phosphoribosyltransferases
has been carried out based on optimal structural superposition.
The active site of hNAPRTase and hNMPRTase shows a high degree
of structural conservation that appears necessary for the binding of
the common substrate PRPP and the highly similar substrates Na
and Nam. Indeed, for the latter case, the pyridine ring recognition
is guaranteed by few strictly conserved residues; in particular, Y21,
H213, R318 in hNaPRTase appear to be structurally equivalent to
Y18, H247 and R311 in hNMPRTase; on the other hand, F193 that
in hNMPRTase provides an aromatic stacking interaction with the
Nam pyridine ring is substituted by L170 in hNaPRTase. Of note
is the observed different conformation of another strictly con-
served residue located in the enzyme active site, i.e. R196 in
hNMPRTase that is equivalent to R171 in hNaPRTase. In the latter,
the positively charged side chain closes up the enzyme active site
and is one of the structural determinants hampering binding of
FK866 to hNaPRTase. When we included in the structural analysis
hQAPRTase, a lower degree of structural conservation amongst all
the three enzymes, emerged. First, the active site in hQAPRTase is
sensibly more positively charged with residues R102, R138, R161,
K139 and K171 all involved in the binding of QA that carries two
carboxylic groups. Among all these residues R102 appears to be
strictly structurally conserved in all the three phosphoribosyltrans-
ferase occupying the equivalent position of R196 in hNAMPTase
and R171 in hNaPRTase. This residue interacts with the functional
moiety present in position 3 of the pyridine ring in all the threeNaPRPP
R 318
H 213
R 171
L 170
G  209
S 214
I 378
ATP
R 318
H 213
R 171
L 170
G  209
S 214
I 378
different ligands. Side chains of residues participating in the binding ligands ((A) Na;
dicated, whereas ligands are depicted as green sticks. Hydrogen bonds are shown as
hNaPRTase
hQAPRTase
hNMPRTase
Fig. 6. Structural comparison of the three human Type II phosphoribosyltransferases involved in NAD biosynthesis. Ribbon representations of human QAPRTase in blue,
NMPRTase in gray and NaPRTase in orange are shown separately (left panel). The structural superposition of the three enzymes is also represented (right panel).
hNaPRTase
hNMPRTase-FK866
FK866
Y 347
G 381
E 246
S 241
S 349
I 378
L 211
P 206
α−14
β−13β−14
β−8
α−13
β−14β−15
β−8
4.5
Fig. 7. FK866-binding-site: structural comparison between hNMPRTase and hNaPRTase. Human NMPRTase structure in complex with its inhibitor FK866 (PDB ID: 2GVJ) is
colored in gray and hNaPRTase is colored in orange. Structural superposition between these two structures highlight, in hNaPRTase, of the tunnel where FK866 binds in
hNMPRTase. Buried surface areas of hNMPRTase (upper left panel) and hNaPRTase (lower left panel) monomers are represented and FK866 is shown as green stick. A ribbon
represented close-up view (right panel) of the superposed secondary structure elements sterically hampering (in hNaPRTase) or permitting (in hNMPRTase) the binding of
FK866. Steric hindrance of FK866 is represented by light green spheres.
426 A.S. Marletta et al. / FEBS Open Bio 5 (2015) 419–428different ligands: QA, Na and Nam. On the other hand, R138 and
R161 in hQAPRTase appear as a peculiar feature of this enzyme
and interact with the second carboxyl group present only in the
structure of QA, in position 2 of its pyridine ring.
3.6. Lack of inhibition by FK866
FK866 is a potent hNMPRTase competitive inhibitor endowed
with a strong antitumor activity and is currently undergoing clin-
ical trials for the treatment of cancer [31]. Surprisingly, FK866 doesnot inhibit hNaPRTase [31] and an explanation of this unexpected
observation is still missing. The inhibitory mechanism of action on
the target has been investigated by structural studies [31]. FK866
binds to hNMPRTase in a tunnel observed at the dimer interface
and deﬁned by the parallel b sheet of the a/b barrel domain of each
monomer [31]. In particular, two small b strands (b14 and b15)
that participate in shaping the tunnel and are located in close prox-
imity of the enzyme’s active site, contribute to the recognition and
binding of FK866. In hNaPRTase the corresponding region (b13 and
b14) revealed a different orientation determined by a 10 residues
A.S. Marletta et al. / FEBS Open Bio 5 (2015) 419–428 427deletion that shorten the preceding alpha helix (a14). The resulting
structural arrangement sterically prevents the binding of FK866 to
hNaPRTase due to severe clashes between the inhibitor and the
protein region deﬁning the tunnel (Fig. 7).
4. Conclusion
NaPRTase is the ﬁrst enzyme in the Preiss–Handler NAD salvage
pathway and therefore has an important role in NAD metabolism,
which is involved in a large number of physiological and patholog-
ical conditions in all organisms. Beyond its role in NAD biosynthe-
sis, it was hypothesized that, in humans, NaPRTase could be linked
to other central metabolic pathways [27] as suggested also for
hACMSD, an enzyme regulating the novo NAD synthesis [52].
Several studies have underlined the NaPRTase importance for
NAD homeostasis in mammals, but no crystallographic data are
available for higher eukaryotes. Our investigations reveal a high
degree of structural conservation at the level of the overall fold
with both bacterial NaPRTase and hNMPRTase. However, while in
the case of the bacterial enzyme the structural similarity extend
also to the active site, signiﬁcant differences emerge in such a
region with hNMPRTase. Indeed, we conﬁrm that the functional
unit of hNaPRTase is a dimer with the active site located at the
domains interface in each monomer, as observed in hNMPRTase.
On the other hand, the structural organization of the active site
in the two enzymes, clearly shows peculiar traits that explain both
the strikingly different substrate speciﬁcity as well as the speciﬁc
inhibitory action of FK866 on hNMPRTase. hNaPRT is a medically
relevant enzyme; its expression levels have been shown to vary
consistently among populations and in different pathological con-
ditions [53–56] including cancer where variants of the enzyme
have also been identiﬁed [54]. Moreover, it has recently been
reported that the adverse effects caused by reactive oxygen species
induced by the treatment with the anticancer hNMPRTase inhibi-
tors (FK866 and analogues), can be reduced by a co-treatment with
nicotinic acid that is linked to the over-expression of hNaPRTases
[57]. Indeed, the administration of nicotinic acid protected
non-tumor cells from toxic effects resulting from depletion of
NAD caused by hNMPRTase inhibition [57]. Therefore, a potential
future effective antitumor therapy targeting NAD biosynthesis
should be featured by both a strong blockage of hNMPRTase to
obtain high toxicity toward tumor cells and no inhibition of
hNaPRTase in order to reduce the toxic effect of the anticancer
drug on non-tumoral cells. The availability of the crystal structure
of both hNMPRTase and hNaPRTase is of high relevance for the
structure-based rational design of potent and selective, i.e. acting
on hNMPRTase only, inhibitors of potential medical relevance. In
conclusion our structural data may ﬁnd application for cancer
treatment and may help in elucidating the complex and yet unclear
interconnections among distinct metabolic pathways in humans.
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